CDC-RFA-PS20-20040401SUPP23: The National Network of Sexually Transmitted Diseases Clinical Prevention Training Centers (NNPTC) Program Supplement
Closed
This grant is closed. A newer notice from the same program is forecast: Holistic and Evidence-Informed Wellness for STI Prevention (CDC-RFA-PS-27-0237). Status: Expected deadline May 31, 2027. It is in our archive of Centers for Disease Control - NCHHSTP notices from 2023.
Centers for Disease Control - NCHHSTP offered grants of up to $800,000 (at least $250,000) to any type of organization. It expected to make about 8 awards worth $550,000 in total. Applications closed on April 13, 2023.
From the official notice on Grants.gov, last changed March 14, 2023. Checked November 7, 2026.
- Award ceiling$800,000
- Award floor$250,000
- Total funding$550,000
- Expected awards8
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | March 14, 2023 |
|---|---|
| Deadline | April 13, 2023 |
| Archived by Grants.gov | May 13, 2023 |
Who can apply
This opportunity was open to any type of organization.
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
This award will be a program supplement intended only for recipients previously awarded under Component A Core, B Core and C Core of CDC-RFA-PS20-2004, National Network of Sexually Transmitted Diseases Clinical Prevention Training Centers (NNPTC).
Is this a realistic fit?
- Past Sexually Transmitted Diseases (STD) Provider Education Grants awards averaged $2.4 million; this notice allows up to $800,000 per award.
- Most of the program's money (50% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
Mpox is a zoonotic infection caused by mpox virus, an orthopoxvirus with an unknown animal reservoir endemic in several Central and West African countries. Since mid-May 2022, the United States and many other countries without a history of mpox activity, have witnessed an increase in reported mpox cases. Although the primary mode of mpox transmission is close contact, meaning that anyone, regardless of gender identity or sexual orientation, can acquire mpox, most of those affected in the current global outbreaks are gay, bisexual, or other men who have sex with men (MSM). Close contact, sustained skin-to-skin contact including sexual contact with a person with mpox or contact with contaminated fomites (e.g., shared linens) are the most significant risk factors associated with human-to-human transmission of mpox virus and many have called to consider mpox a sexually transmitted infection (STI). Not only is the clinical presentation of mpox similar to some STIs, such as syphilis, herpes, lymphogranuloma venereum (LGV), or other etiologies of proctitis, but co-infections of mpox with STIs are common. Although the case-fatality rate for mpox in the current outbreak is low, infection can cause a significant degree of pain and morbidity, including hospitalization. There is no treatment specifically for mpox. However, because the mpox and smallpox viruses are closely related, drugs and vaccines developed to protect against smallpox may be used to prevent and treat mpox virus infections. Vaccination can be given as post-exposure prophylaxis (PEP) or as pre-exposure prophylaxis (PrEP).The National Network of Sexually Transmitted Diseases Clinical Prevention Training Centers (NNPTC) are regional and national centers created in partnership with health departments and universities. NNPTC is dedicated to increasing the knowledge and skills of health professionals in the areas of sexual and reproductive health. The NNPTCs are well positioned to address mpox in the United States for several reasons including: 1) established expertise in infections transmitted through sexual contact 2) content expertise focused on MSM populations; 3) broad geographical reach of the network which covers the entire United States; 4) faculty with deep expertise in infectious diseases and public health. The purpose of this non-competitive supplemental Notice of Funding Opportunity (NOFO) is to fund components A, B, and C of the PS20-2004 NNPTC NOFO.
Who has won Sexually Transmitted Diseases (STD) Provider Education Grants grants before
From fiscal 2021 to 2025, Sexually Transmitted Diseases (STD) Provider Education Grants (93.978) awarded $50.4 million across 21 grant awards, an average of $2.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Denver Health and Hospital Authority | Colorado | 2 | $7.8 million |
| The Regents of the University of California, San Francisco | California | 3 | $6.6 million |
| University of Washington | Washington | 1 | $6.4 million |
| Altarum Institute | Michigan | 2 | $5.5 million |
| The Trustees of Columbia University in the City of New York | New York | 1 | $3.2 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, CDC-RFA-PS-27-0237, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-PS20-20040401SUPP23 still open?
No. It closed on April 13, 2023. A newer notice is forecast: CDC-RFA-PS-27-0237, expected deadline May 31, 2027.
Who can apply for The National Network of Sexually Transmitted Diseases Clinical Prevention Training Centers (NNPTC) Program Supplement?
Centers for Disease Control - NCHHSTP accepted applications from any type of organization. The notice adds further conditions, so read its eligibility section.
What is the deadline for The National Network of Sexually Transmitted Diseases Clinical Prevention Training Centers (NNPTC) Program Supplement?
Closed April 13, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $800,000 each. About $550,000 in total across about 8 awards.
Who has won Sexually Transmitted Diseases (STD) Provider Education Grants grants before?
The largest recipients over five fiscal years were Denver Health and Hospital Authority, The Regents of the University of California, San Francisco, University of Washington. The program made 21 awards worth $50.4 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)